Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.
The antitumor effect of paclitaxel, epirubicin, and both in combination was tested using R-27, an estrogen receptor-positive human breast carcinoma. In an in vivo study using nude mice both drugs showed an additive effect, whereas they showed a supraadditive pattern in in vitro MTT assay. The combination of paclitaxel and epirubicin may enhance the antitumor effect on breast carcinoma.